iRadimed (NASDAQ:IRMD) Issues Q4 2025 Earnings Guidance

iRadimed (NASDAQ:IRMD) updated its fourth quarter 2025 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 0.470-0.510 for the period, compared to the consensus estimate of 0.470. The company issued revenue guidance of $21.4 million-$22.4 million, compared to the consensus revenue estimate of $20.7 million. iRadimed also updated its FY 2025 guidance to 1.840-1.880 EPS.

iRadimed Stock Performance

NASDAQ:IRMD opened at $84.11 on Tuesday. iRadimed has a fifty-two week low of $47.48 and a fifty-two week high of $85.00. The business has a 50 day moving average price of $73.39 and a 200-day moving average price of $64.07. The firm has a market cap of $1.07 billion, a PE ratio of 51.92 and a beta of 1.02.

iRadimed Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, November 25th. Stockholders of record on Friday, November 14th will be issued a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Friday, November 14th. iRadimed’s dividend payout ratio is currently 41.98%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Weiss Ratings restated a “buy (b)” rating on shares of iRadimed in a report on Friday. Wall Street Zen lowered iRadimed from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 26th. Roth Capital set a $90.00 target price on iRadimed in a report on Friday. Finally, Lake Street Capital reaffirmed a “buy” rating and issued a $100.00 price target on shares of iRadimed in a research note on Monday. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $87.33.

Insiders Place Their Bets

In related news, CEO Roger E. Susi sold 5,000 shares of iRadimed stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $77.69, for a total transaction of $388,450.00. Following the completion of the transaction, the chief executive officer directly owned 2,327,500 shares of the company’s stock, valued at $180,823,475. This trade represents a 0.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Monty K. Allen sold 1,102 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $69.10, for a total value of $76,148.20. Following the completion of the sale, the director directly owned 19,898 shares in the company, valued at approximately $1,374,951.80. This represents a 5.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 36,102 shares of company stock worth $2,623,848. Company insiders own 36.80% of the company’s stock.

Institutional Investors Weigh In On iRadimed

Institutional investors have recently modified their holdings of the stock. Osaic Holdings Inc. raised its position in shares of iRadimed by 766.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,813 shares of the medical equipment provider’s stock worth $228,000 after purchasing an additional 3,373 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares during the last quarter. Lazard Asset Management LLC raised its holdings in iRadimed by 5.2% in the second quarter. Lazard Asset Management LLC now owns 41,110 shares of the medical equipment provider’s stock worth $2,457,000 after buying an additional 2,036 shares during the last quarter. Brevan Howard Capital Management LP bought a new position in shares of iRadimed in the second quarter worth approximately $260,000. Finally, Jane Street Group LLC raised its holdings in iRadimed by 30.5% in the 2nd quarter. Jane Street Group LLC now owns 9,183 shares of the medical equipment provider’s stock worth $549,000 after acquiring an additional 2,145 shares during the last quarter. 92.34% of the stock is owned by hedge funds and other institutional investors.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.